Plain-English translation of NCT06967038 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing therapy, a new treatment that uses your own immune cells specially engineered in a laboratory to recognize and attack lymphoma cells. The study focuses on people who have both primary Sjogren's syndrome (an autoimmune condition affecting moisture-producing glands) and lymphoma (a type of blood cancer). Researchers will carefully test different doses of this treatment to see what dose works best and is safest for patients.
People with primary Sjogren's syndrome have an increased risk of developing lymphoma, and current treatments don't always work well for these high-risk patients. This trial exists to see whether this new cell-based therapy can offer a better option for patients with both conditions.
You likely qualify if…
You likely don't qualify if…
As a participant, you would receive infusions of the engineered natural killer cells through your veins. The trial uses a careful dose-escalation approach, meaning early participants receive lower doses and later participants may receive higher doses if safety is confirmed. You would be closely monitored for at least 45 days after your first infusion to watch for any side effects, with careful tracking of how your body responds to the treatment.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China